U.S. Central Nervous System Biomarkers Market Size, Share & Forecast 2026–2032
Report Highlights
- ✓Country: United States
- ✓Market: Central Nervous System Biomarkers Market
- ✓Market Size 2024: USD 1.42 billion
- ✓Market Size 2032: USD 2.61 billion
- ✓CAGR: 7.9%
- ✓Base Year: 2025
- ✓Forecast Period: 2026–2032
Analyst Recommendation — Secure Analyzer Placements Early: Diagnostics manufacturers and reference laboratories should secure hospital analyzer placements with at least three large health systems before the end of 2026, since installed-base contracts will lock in reagent revenue through 2032.
CNS Biomarkers in the U.S.: Competitive Overview
The U.S. CNS biomarkers market is concentrated at the instrument level and fragmented at the test level. Roche Diagnostics, Fujirebio, Siemens Healthineers and Beckman Coulter hold most installed immunoassay analyzers in hospital laboratories, while Quanterix and Alamar Biosciences compete on high-sensitivity single-molecule and proteomic platforms. Few independent developers own both the analyzer and the reagent economics, and reference laboratories Labcorp and Quest Diagnostics control test distribution and billing access.
International manufacturers dominate instrument supply, whereas domestic players dominate laboratory services and direct-to-clinician channels. C2N Diagnostics, based in St. Louis, competes through its PrecivityAD2 mass spectrometry test offered as a laboratory-developed test, which bypasses some analyzer lock-in. Competitive advantage in this country depends on FDA clearance status, CMS reimbursement coding, installed analyzer footprint, and integration with electronic health record ordering workflows.
Demand Drivers Shaping CNS Biomarkers in the U.S.
Aging demographics and rising Alzheimer's diagnosis rates are the largest volume driver. Medicare coverage of anti-amyloid monoclonal antibodies, lecanemab and donanemab, requires confirmed amyloid pathology before treatment, which expands testing demand in neurology clinics. Eli Lilly and Eisai benefit indirectly, because each prescription pulls a biomarker confirmation test that diagnostics vendors capture.
Expansion of blood-based testing into primary care is the second driver. Federal reimbursement for plasma-based amyloid tests favors vendors with national collection networks, so Labcorp and Quest Diagnostics gain share against smaller specialty laboratories. Third, electronic health record integration of ordering and result workflows rewards platforms that connect directly to Epic and Oracle Health, giving large immunoassay manufacturers a structural advantage.
Competitive Restraints and Market Challenges
Price pressure is intensifying as multiple plasma assays enter the market. Medicare Clinical Laboratory Fee Schedule rates limit the premium that new entrants can command, and payers increasingly demand head-to-head performance data before granting coverage. Smaller developers without installed analyzer bases face margin compression, which is driving consolidation through acquisitions by larger diagnostics groups.
The FDA's 2024 final rule on laboratory-developed tests, whose implementation a federal court blocked in 2025, created uncertainty that raised compliance planning costs for single-site developers. Specialized neuropathologists and clinical chemists remain scarce, and many community hospitals lack the mass spectrometry capacity needed for confirmatory testing. Infrastructure gaps in rural counties further restrict competitive reach beyond academic medical centers.
Growth Opportunities for Market Players
Primary care screening and pre-symptomatic risk stratification represent the largest untapped segment. Vendors building plasma assays suited to primary care collection target community clinics that currently refer patients to specialists for confirmation. Partnerships with retail health providers and telehealth platforms offer distribution routes that bypass traditional hospital procurement cycles.
Parkinson's disease, frontotemporal dementia, and multiple sclerosis present adjacent opportunities as alpha-synuclein seed amplification assays and neurofilament light chain tests mature. Quanterix and Alamar Biosciences are positioned to supply multiplex panels to pharmaceutical sponsors running clinical trials, where biomarker enrichment determines enrollment. Companion diagnostic agreements with drug sponsors generate recurring revenue that stands apart from reimbursement-dependent testing.
Market at a Glance
| Metric | Details |
|---|---|
| Market Size 2024 | USD 1.42 billion |
| Market Size 2032 | USD 2.61 billion |
| Growth Rate (CAGR) | 7.9% |
| Most Critical Decision Factor | Installed analyzer footprint and reimbursement coding access |
| Largest Region | Northeast U.S. |
| Competitive Structure | Oligopolistic instruments, fragmented testing services |
Leading Market Participants
- Roche Diagnostics
- Fujirebio
- Quanterix
- C2N Diagnostics
- Labcorp
- Quest Diagnostics
- Siemens Healthineers
- Beckman Coulter
- Bio-Rad Laboratories
- Alamar Biosciences
Regulatory and Policy Environment
The FDA regulates CNS biomarker assays through 510(k), De Novo, and Breakthrough Devices Program pathways, and clearance status directly determines which vendors can sell into hospital laboratories without restriction. The Clinical Laboratory Improvement Amendments of 1988, administered by CMS, govern laboratory certification, while the Protecting Access to Medicare Act framework sets Clinical Laboratory Fee Schedule rates that Congress has repeatedly delayed. These rules favor established manufacturers with regulatory affairs teams and penalize small developers.
CMS's 2022 national coverage determination for anti-amyloid antibodies imposed a registry requirement under coverage with evidence development, which shapes how biomarker confirmation data is collected and reported. Medicare reimbursement for amyloid testing depends on documented clinical pathways, so vendors that supply payer evidence packages secure preferred access. Competitive positioning therefore rests on regulatory strategy as much as analytical performance.
Competitive Outlook for CNS Biomarkers in the U.S.
By 2032, instrument supply will remain concentrated among four or five global diagnostics manufacturers, while test volume will shift toward reference laboratories with national collection networks. Plasma assays will become the default first-line test in neurology and primary care, compressing the share held by PET imaging and cerebrospinal fluid testing. Vendors that secure hospital analyzer placements early will hold the strongest reagent revenue positions.
Consolidation is the most probable structural change, as smaller developers without installed bases are acquired by large diagnostics groups seeking neurology menus. Domestic companies such as C2N Diagnostics and Quanterix will compete on specialized platforms and pharmaceutical partnerships rather than hospital instrument volume. Competitive success will increasingly depend on payer evidence, regulatory agility, and integration into electronic health record ordering systems.
Frequently Asked Questions
Market Segmentation
- Immunoassay Analyzers and Reagents
- Mass Spectrometry Platforms
- PET Imaging Tracers
- Genetic and Molecular Assays
- Alzheimer's Disease
- Parkinson's Disease
- Multiple Sclerosis
- Frontotemporal Dementia
- Hospitals
- Reference Laboratories
- Academic Medical Centers
- Pharmaceutical Sponsors
Table of Contents
Research Framework and Methodological Approach
Information
Procurement
Information
Analysis
Market Formulation
& Validation
Overview of Our Research Process
MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.
1. Data Acquisition Strategy
Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.
- Company annual reports & SEC filings
- Industry association publications
- Technical journals & white papers
- Government databases (World Bank, OECD)
- Paid commercial databases
- KOL Interviews (CEOs, Marketing Heads)
- Surveys with industry participants
- Distributor & supplier discussions
- End-user feedback loops
- Questionnaires for gap analysis
Analytical Modeling and Insight Development
After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.
2. Market Estimation Techniques
MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.
Bottom-up Approach
Aggregating granular demand data from country level to derive global figures.
Top-down Approach
Breaking down the parent industry market to identify the target serviceable market.
Supply Chain Anchored Forecasting
MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.
Supply-Side Evaluation
Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.
3. Market Engineering & Validation
Market engineering involves the triangulation of data from multiple sources to minimize errors.
Extensive gathering of raw data.
Statistical regression & trend analysis.
Cross-verification with experts.
Publication of market study.
Client-Centric Research Delivery
MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.